INCY · Company research
12 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Incyte expects to report results from its Registrational combination study study of Niktimvo (axatilimab) + ruxolitinib for Newly diagnosed chronic graft-versus-host disease in the second half of 2026 (no exact date yet). Registrational combination study is a study designed to support approval.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte expects European regulators to decide on Povorcitinib for Moderate to severe hidradenitis suppurativa in the second half of 2026 (no exact date yet). An approval lets the company start selling it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte expects to report results from its Phase 1 study of INCA033989 for mutCALR myelofibrosis (mono and with ruxolitinib) in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
INCB123667 (CDK2) Phase 3 first-line maintenance ovarian cancer start, expected in the second half of 2026 (no exact date yet). A company milestone for Incyte (INCB123667 for First-line maintenance ovarian cancer): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte presents data on INCB161734 for Metastatic PDAC (with mFOLFOX/GemNabP) and mCRC (with cetuximab) at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte presents data on INCB123667 for Recurrent epithelial ovarian cancer at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte presents data on INCA33890 for MSS colorectal cancer at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte expects to report results from its Phase 3 study of Povorcitinib for Moderate to severe prurigo nodularis in Q4 2026 (Oct–Dec) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte expects to report results from its Phase 3 study of Opzelura (ruxolitinib cream) for Mild-to-moderate hidradenitis suppurativa in Q4 2026 (Oct–Dec) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte expects regulators to decide on Povorcitinib for Moderate to severe hidradenitis suppurativa in Q1 2027 (Jan–Mar) (no exact date yet). An approval lets the company start selling it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte expects regulators to decide on Monjuvi (tafasitamab) for Newly diagnosed diffuse large B-cell lymphoma in Q1 2027 (Jan–Mar) (no exact date yet). An approval lets the company start selling it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Povorcitinib vitiligo regulatory submissions planned, expected in the first half of 2027 (no exact date yet). A company milestone for Incyte (povorcitinib for Nonsegmental vitiligo): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
European regulators approved Incyte’s Opzelura (ruxolitinib cream) for Moderate atopic dermatitis (EU) in Q3 2026 (Jul–Sep). The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte presented data on tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R-CHOP for Previously untreated high-risk DLBCL / high-grade B-cell lymphoma at a medical meeting on May 30, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA told Incyte it won’t approve Zynyz (retifanlimab-dlwr) for Metastatic non-small cell lung cancer yet (Mar 6, 2026). The letter lists what has to be fixed before the application can be approved; many drugs get there after a resubmission.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to INCY.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.